Table 3.
Multivariate Analysis of Prognostic Factors for the Whole Cohort
| End Points | HR (95% CI) | P Value⁎ |
|---|---|---|
| OS | ||
| Age, ≤50 years vs >50 years | 2.60 (1.36-4.96) | .004 |
| Sex, men vs women | 0.43 (0.14-1.31) | .137 |
| History of smoking, no vs yes | 1.35 (0.67-2.68) | .400 |
| T stage, T1-2 vs T3-4 | 1.68 (0.72-3.94) | .233 |
| N stage, N0-1 vs N2-3 | 1.52 (0.70-3.30) | .295 |
| Clinical stage, II-III vs IVA-B | 12.07 (1.02-4.20) | .043 |
| Cervical dose, ≤64 vs >64 Gy | 1.85 (0.95-3.59) | .071 |
| DMFS | ||
| N stage, N0-1 vs N2-3 | 1.65 (0.66-4.14) | .285 |
| Clinical stage, II-III vs IVA-B | 12.26 (0.96-5.29) | .061 |
| Cervical dose, ≤ 64 vs > 64 Gy | 2.00(0.90,4.45) | .088 |
| PFS | ||
| Age, ≤ 50 years vs > 50 years | 1.63 (1.01-2.64) | .045 |
| Clinical stage, II-III vs IVA-B | 11.71 (1.02-2.85) | .040 |
Values in bold are significant (P < .05).
⁎
P values were calculated with an adjusted Cox proportional-hazards model.